Ontology highlight
ABSTRACT:
SUBMITTER: Fontebasso AM
PROVIDER: S-EPMC4282994 | biostudies-literature | 2014 May
REPOSITORIES: biostudies-literature
Fontebasso Adam M AM Papillon-Cavanagh Simon S Schwartzentruber Jeremy J Nikbakht Hamid H Gerges Noha N Fiset Pierre-Olivier PO Bechet Denise D Faury Damien D De Jay Nicolas N Ramkissoon Lori A LA Corcoran Aoife A Jones David T W DT Sturm Dominik D Johann Pascal P Tomita Tadanori T Goldman Stewart S Nagib Mahmoud M Bendel Anne A Goumnerova Liliana L Bowers Daniel C DC Leonard Jeffrey R JR Rubin Joshua B JB Alden Tord T Browd Samuel S Geyer J Russell JR Leary Sarah S Jallo George G Cohen Kenneth K Gupta Nalin N Prados Michael D MD Carret Anne-Sophie AS Ellezam Benjamin B Crevier Louis L Klekner Almos A Bognar Laszlo L Hauser Peter P Garami Miklos M Myseros John J Dong Zhifeng Z Siegel Peter M PM Malkin Hayley H Ligon Azra H AH Albrecht Steffen S Pfister Stefan M SM Ligon Keith L KL Majewski Jacek J Jabado Nada N Kieran Mark W MW
Nature genetics 20140406 5
Pediatric midline high-grade astrocytomas (mHGAs) are incurable with few treatment targets identified. Most tumors harbor mutations encoding p.Lys27Met in histone H3 variants. In 40 treatment-naive mHGAs, 39 analyzed by whole-exome sequencing, we find additional somatic mutations specific to tumor location. Gain-of-function mutations in ACVR1 occur in tumors of the pons in conjunction with histone H3.1 p.Lys27Met substitution, whereas FGFR1 mutations or fusions occur in thalamic tumors associate ...[more]